-

Kernel Introduces Flow2: Revolutionary Advanced Neuroimaging Technology Enabling Precision Neuromedicine

LOS ANGELES--(BUSINESS WIRE)--Kernel, a pioneer in neuroimaging technology, is proud to unveil its groundbreaking Flow2 system, a major leap forward in the field of functional neuroimaging. With Flow2, researchers and clinicians now have unprecedented access to robust, fMRI-like functional neuroimaging in a quick and user-friendly headset, making precision neuromedicine more accessible than ever before.

Flow2 incorporates state-of-the-art time-domain functional near-infrared spectroscopy (TD-fNIRS) technology along with electroencephalography (EEG). This unique combination provides an exceptionally comprehensive view of brain activity, enabling researchers and clinicians to delve deeper into the intricate workings of the brain. TD-fNIRS measures changes in oxygenation levels in the brain's cortical regions, offering high-resolution insights similar to fMRI, while EEG captures the electrical brain waves, providing additional information about neural dynamics. This integration of TD-fNIRS and EEG in Flow2 coupled with the ease of use, portability and scalability, unlocks unprecedented possibilities for studying brain function, developing robust biomarkers, and deeply characterizing new therapies.

"Flow2 is a game-changer in the field of neuroimaging," said Ryan Field, PhD, CEO of Kernel. "We now have a tool that can generate sufficient data to feed modern AI tools and draw new insights that will power the emerging field of precision neuromedicine. There are many questions that have yet to be answered because a standardized, robust, and scalable source of functional brain data was unavailable, until now."

The Flow technology has been validated through a series of publications demonstrating both the raw system performance and its ability to measure meaningful responses to psychoactive substances. Flow2 builds on these successes and has been launched into a number of research settings as we start to build the next generation of use cases around highly-scalable neuroimaging.

"Our team has been working for five years to perfect the technology inside of Flow2 and it’s now ready for widespread use," noted Field. "Our mission at Kernel is to use Flow2 to build the world's most comprehensive portfolio of brain-based biomarkers. The robust and information-rich biomarkers that we’re building are going to enable completely new types of neuroscience development to be done.”

About Kernel:

Kernel is a trailblazer in the field of neuroimaging technology, dedicated to advancing precision neuromedicine. By developing innovative and accessible solutions, Kernel aims to build the world's most comprehensive portfolio of brain-based biomarkers, revolutionizing the treatment of mental and brain health.

Contacts

Press Contact
Rebecca Baken
press@kernel.com

Kernel


Release Versions

Contacts

Press Contact
Rebecca Baken
press@kernel.com

Social Media Profiles
More News From Kernel

Kernel Launches Observational Study Using Flow2 Neuroimaging Technology to Identify Biomarkers of Depression Treatment Response

LOS ANGELES--(BUSINESS WIRE)--Kernel, an innovator in non-invasive neuroimaging technology, announces the first patient has been measured in an observational study of depression treatments using Kernel’s revolutionary Flow2 neuroimaging technology. The initial launch sites include Kadima Neuropsychiatry Institute, Bespoke Treatment, and ATP Clinical Research. The study utilizes Flow2 to measure patients as they undergo treatment, paving the way to transform how depression is treated with patien...

Kernel Launches Cognitive Decline Study Using Flow2 Neuroimaging Technology

LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging technology, is excited to announce the commencement of an observational study focused on characterizing early cognitive decline. The first patients in this study have been measured at the Neurology Center of Southern California (a Profound Research site), one of Kernel’s partners in this study. By leveraging the advanced capabilities of the Flow2 neuroimaging technology, this groundbreaking study aims to detect Mild Cog...

Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects

LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS," in the journal Scientific Reports from the Nature Portfolio of Journals. The study, sponsored by Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), underscores the ability of Kernel’s Flow1 system to capture and analyze brain changes resulting from the administration of a psych...
Back to Newsroom